Blogs

WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies

(More on Colombia here: http://keionline.org/colombia)

On May 24, 2016, Colombia's Minister of Health, Alejandro Gaviria, made an intervention at the World Health Assembly that referred to the pressure Colombia has been facing with regard to the potential compulsory license for imatinib and called for the WHO to support members to ensure sustainable development through the regulation of pharmaceutical monopolies and promoting competition, transparency, and the rational use of drugs.

Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License

Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch's office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked.

13 non-profits urge Senate HELP Committee to block floor amendments to 21st Century Cures Act counterpart

Before the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) presents a legislative package of healthcare reforms to the Senate floor for an up-or-down vote, 13 consumer, patient and health non-profit groups sent a letter to HELP Chairman and Ranking Member to ensure that the final legislative package includes only those bills that the HELP Committee reviewed in mark-up sessions.

122 experts defend Colombia's right to issue compulsory license on imatinib in face of U.S. pressure

(More on Colombia here: http://keionline.org/colombia)

On May 16, 2016, 122 health, trade, and intellectual property experts defended the Colombian government's right to issue a compulsory license on imatinib, an expensive leukemia drug that is being sold at a high price by the Swiss drug company Novartis, in a letter to Colombian President Juan Manuel Santos.

SCCR32 Day 4 Strong statement on education by the American University PIJIP

sean-x1024_0.jpg

Speaking on behalf of the American University programme on information justice and Intellectual Property. And I speak as an educator myself and also on behalf of a larger network that I coordinate called the global expert network on user rights which is a network of educators.

April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents

Update: english translation of letter now available at end this blog.

SCCR 32 KEI on Orphan Works

keiorphan.jpgKEI Statement SCCR 32 Day 4 on "Orphan works" and Libraries and Archives

I will be speaking here as a user of libraries and archives and as a user of out of print and orphan works for my past academic work and my research today.

April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license

(More on Colombia here: http://keionline.org/colombia)

Updated to include English translation of letter. Note that KEI also has copy of the letter of April 28, 2016, reporting on the meeting with Eissenstat here.

Fundación Karisma at WIPO SCCR32 on broadcast treaty

Karisma-1280x.jpg

Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.

KEI Comments to DHHS on WHA 69 re CEWG, Nocommunicable Diseases

Today the Department of Health and Human Services held their annual WHA listening session. This year HHS sent an email the day prior announcing that the usual 3 minute allotment would be cut in half to 90 seconds. This decision caused several NGOs to not attend.

Xtandi patient on Medicare — with supplement — pays $441.97 per month

Astellas has claimed that patients taking Xtandi face very small co-payments. One patient living in Arizona contacted KEI with proof that Astellas' claims just aren't true. The patient, who is on Medicare, provided a copy of a summary of his expenses for the first quarter of of 2016.

His monthly patient co-payment is $441.97 a month.

2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses

In response to a February request under the Freedom of Information Act (FOIA) for documents related to the grant of an exclusive patent license on a HER2+ breast cancer treatment technology, the National Institutes of Health (NIH) withheld in full all responsive records.

WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDS

On Monday, 2 May 2016, the World Health Organization (WHO) convened the 2016 open-ended member states meeting of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). The 2016 CEWG is chaired by Bhanu Pratap Sharma, Secretary, Ministry of Health and Family Welfare, Government of India. The Vice-Chair is Tania Dussey- Cavassini, Vice-Director General, Ambassador for Global Health, Federal Office of Public Health, Switzerland.

Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&D

On April 26, 2016, Congressman Lloyd Doggett (D-Texas) delivered the keynote address at a panel discussion on drug pricing at the Center for American Progress, where he addressed the Federal government’s role in subsidizing drug development, ensuring affordable access at reasonable prices for U.S. citizens, industry practices related to monopoly pricing, and legislative solutions to promote rational and affordable drug prices.

Syndicate content